Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: A phase II study of the SUOC group

2011 ◽  
Vol 102 (6) ◽  
pp. 1171-1175 ◽  
Author(s):  
Hiroshi Kitamura ◽  
Keisuke Taguchi ◽  
Yasuharu Kunishima ◽  
Masahiro Yanase ◽  
Atsushi Takahashi ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
Second Line ◽  
Metastatic Urothelial Carcinoma

Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study

2007 ◽  
Vol 18 (4) ◽  
pp. 487-491 ◽  
Author(s):  
Chia-Chi Lin ◽  
Chih-Hung Hsu ◽  
Chao-Yuan Huang ◽  
Hsiao-Yi Keng ◽  
Yu-Chieh Tsai ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
Second Line ◽  
Metastatic Urothelial Carcinoma

A phase II study of single-agent nab-paclitaxel as second-line therapy in patients with metastatic urothelial carcinoma.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. TPS231-TPS231 ◽  
Author(s):  
S. S. Sridhar ◽  
C. M. Canil ◽  
S. D. Mukherjee ◽  
E. Winquist ◽  
C. Elser ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Single Agent ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Metastatic Urothelial Carcinoma

Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature

2019 ◽  
Vol 63 (4) ◽  
Author(s):  
Salvatore Grisanti ◽  
Vittorio D. Ferrari ◽  
Michela Buglione ◽  
Giorgio M. Agazzi ◽  
Roberto Liserre ◽  
...  
Keyword(s):  
Systematic Review ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Recurrent Glioblastoma ◽  
Line Treatment ◽  
Second Line ◽  
Review Of Literature

Randomized Phase II Study of PARP Inhibitor Veliparib with Modified FOLFIRI versus FOLFIRI as Second Line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

2021 ◽  
pp. clincanres.1789.2021
Author(s):  
E. Gabriela Chiorean ◽  
Katherine A Guthrie ◽  
Philip A Philip ◽  
Elizabeth M. Swisher ◽  
Florencia Jalikis ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Parp Inhibitor ◽  
Metastatic Pancreatic Cancer ◽  
Line Treatment ◽  
Second Line ◽  
Randomized Phase Ii

scholarly journals Phase II study of evofosfamide (TH-302) monotherapy as a second-line treatment in advanced biliary tract cancer

2018 ◽  
Vol 29 ◽  
pp. viii259
Author(s):  
J.S. Yoon ◽  
K.-H. Lee ◽  
G.J. Cheon ◽  
Y.-J. Bang ◽  
D.-Y. Oh
Keyword(s):  
Biliary Tract ◽  
Phase Ii ◽  
Biliary Tract Cancer ◽  
Phase Ii Study ◽  
Line Treatment ◽  
Second Line ◽  
Tract Cancer
Sign in / Sign up

Export Citation Format

Share Document